In a report issued on July 21, Cory Kasimov from J.P. Morgan maintained a Buy rating on GW Pharma (GWPH), with a price target of $187.00. The company’s shares closed last Monday at $128.75.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.1% and a 58.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on GW Pharma is a Strong Buy with an average price target of $175.22, representing a 37.9% upside. In a report issued on July 8, H.C. Wainwright also maintained a Buy rating on the stock with a $161.00 price target.
The company has a one-year high of $175.35 and a one-year low of $67.98. Currently, GW Pharma has an average volume of 331.3K.
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GWPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.